Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports

paythelady.612 shared this article with you from Inoreader Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 Apr 6;9(10):2326-2333. doi: 10.12998/wjcc.v9.i10.2326. ABSTRACT BACKGROUND: Bedaquiline is among the prioritized drugs recommended by the World Health Organization for the treatment of extensively drug-resistant tuberculosis (XDR-TB). Many patients have not achieved better clinical improvement after bedaquiline is stopped at 24 wk. However, there is no recommendation or guideline on bedaquiline administration beyond 24 wk, which is an important consideration when balancing the benefit of prognosis for XDR-TB against the uncertain safety concerning the newer antibiotics. CASE SUMMARY: This paper reported 2 patients with XDR-TB (a female of 58 years of age and a female of 18 years of age) who received bedaquiline for 36 wk, as local experience to be shared. The 2 cases had negative cultures after 24 wk of treatment, but lung imaging was still positive. After discussion among experts, the consensus was made to bedaquiline prolongation by another 12 wk. The 36-wk prolonged use of bedaquiline in both cases achieved a favorable response without increasing the risk of cardiac events or new safety signals. CONCLUSION: Longer regimen, including 36-wk bedaquiline treatment, might be an option for patients with XDR-TB. More studies are needed to explore the effectiveness and safety of prolonged use of bedaquiline for 36 wk vs standard 24 wk in the treatment of multidrug-resistant/XDR-TB or to investigate further the biomarkers and criteria indicative for extension of bedaquline to facilitate clinical use of this novel drug. PMID:33869610 | PMC:PMC8026830 | DOI:10.12998/wjcc.v9.i10.2326 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.